Partnering & collaboration
We are eighteen months old. Almost everything we do well, we do with someone else.
Clinical study sites
We are adding sites for all four medicines and for the Lumavue post-market study, with a preference for centres that can enrol the specific biology we are selecting for.
Device evaluation partners
Hospitals willing to put prototypes in a simulation lab and tell us what is wrong with them.
Academic collaboration
Funded partnerships on target biology, biomaterials and surgical imaging, with publication rights protected.
In-licensing
Preclinical and early clinical assets in our four therapeutic areas, particularly where human genetics is strong.
Manufacturing
Clinical supply for oligonucleotides, small molecules and sterile single-use device components.
Distribution
Regional distribution partners for Lumavue outside the southeastern United States.
How to reach us
Send a non-confidential summary — what it is, what stage, the key data, and what you want from us. We aim to respond within 10 business days. Please do not send confidential information before a confidentiality agreement is in place.
Investigator-initiated studies
Baxtra supports research designed and sponsored by external investigators where it addresses a genuine gap. The investigator remains the sponsor and retains publication rights, including for negative results.
What we can support
Study product supply, funding, or both. Support is never conditional on purchasing or prescribing behaviour.
Review process
Concepts are reviewed monthly by an internal scientific committee with two external members. Decisions typically take four to six weeks.
Publication
Investigators commit to publishing or posting results within 12 months of completion, whatever the outcome.